Cyprotex - News
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more here.

Cyprotex PLC - Board Change

4 September 2012 - Cyprotex (AIM:CRX), the specialist preclinical contract research organisation (CRO), today announces the resignation of Katya Tsaioun, PhD, with immediate effect.

Dr Tsaioun has served as Cyprotex's Chief Scientific Officer and Director since the August 2010 acquisition of its U.S based subsidiary Apredica, where she was President and co-founder.

As part of the Apredica purchase agreements, Dr. Tsaioun planned to remain with the combined companies for two years. During her tenure at Cyprotex, Dr, Tsaioun led Cyprotex into three new markets: high content in vitro toxicology, in vitro topical and cosmetic testing, and genomic ADME services.

The Company wishes to extend its gratitude for Dr. Tsaioun’s contributions as a Director and CSO and wishes her well in her future endeavours.


Cyprotex PLC  Tel:  +44 (0) 1625 505 100
Dr Anthony Baxter, Chief Executive Officer
John Dootson, Chief Financial Officer
Mark Warburton, Chief Operating Officer and Legal Counsel

Singer Capital Markets Limited (Nomad and broker to Cyprotex) Tel:  +44 (0)20 7496 3000
Shaun Dobson

Claes Spang

FTI Consulting Tel:  +44 (0) 20 7831 3113
Simon Conway
Mo Noonan

Contact us

News categories


Contact us to discuss your ADME Tox issues or request a quote

North America (East Coast): 888-297-7683
Europe: +44 1625 505100


or fill out the form below:

Please give details of the assays you are interested in. Where appropriate please specify one or more species (human, rat, mouse etc.), isoforms (CYP1A1,CYP1B1, etc) or other relevant details.